Matthias D. Hofer

Oct 4, 2024 | globalarbitrationreview.com | Eric Leikin |Lutz Riede |Matthias D. Hofer |Sue Ng

In summaryTechnology is fundamentally shifting the way in which individuals, businesses and governments interact with one another – bringing both opportunities and risks, including the increased risk of disputes. We see the most notable developments being the (continued) explosive growth of artificial intelligence (AI) and the EU’s ambitious efforts to serve as the vanguard of tech regulation.

Jul 12, 2023 | tt.com | Matthias D. Hofer

Kommentarvon Matthias Hofer Mittwoch, 12.07.2023, 04:55shareArtikel teilenhomeZur StartseiteVerwandte ThemenAus der ZeitungKommentarMeinungGesellschaftPanorama

May 16, 2023 | lexology.com | Lutz Riede |Giles Pratt |Matthias D. Hofer |Alexandra Morgan

SpeedreadLast week, we reported that the European Parliament is pushing forward with the adoption of the Artificial Intelligence Act (AI Act). Among the amendments to the European Commission’s original text are new disclosure obligations that require providers of AI models (such as Generative AI systems) to disclose any copyright materials used for training those models. As drafted, the disclosure obligations appear far-reaching but are not very clear.

May 4, 2023 | dolomitenstadt.at | Matthias D. Hofer

Der Lehrermangel in Tirol betrifft alle Schultypen Die Zeit der Sonntagsreden ist im Schulbereich definitiv vorbei.

Mar 13, 2023 | imperial.ac.uk | Matthias D. Hofer

While the UK has been slower than the EU to approve some novel medicines, and still relies heavily on EU decision-making, there have also been encouraging results from the early steps made to fast-track new drugs. In our research, we’ve investigated official records of drug approvals and drawn comparisons between the performance of the UK regulatory body, Medicine and Healthcare products Regulatory Agency (MHRA), and its international counterparts in the EU, US and Switzerland.